AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29394351 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-Space Assessment for Persons with Cognitive Impairment (LSA-CI)
Number of subjects: 118
Study 27161603 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF contact lenses
Number of subjects: 52
Study 26411031 — intervention group
Group type: EXPERIMENTAL
Intervention: CQR-300, 300 mg daily
Number of subjects: 0
Study 24680843 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer locked/unlocked suture
Number of subjects: 36
Study 24680843 — intervention group
Group type: COMPARATOR
Intervention: Single-layer locked suture
Number of subjects: 36
Study 23152674 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 93
Study 23152674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 19729582 — intervention group
Group type: EXPERIMENTAL
Intervention: BtxA + mCIMT
Number of subjects: 32
Study 19729582 — intervention group
Group type: COMPARATOR
Intervention: BtxA + conventional rehabilitation
Number of subjects: 32
Study 18829797 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of infusion of intravenous fat emulsion
Number of subjects: 110
Study 18829797 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 16060411 — intervention group
Group type: COMPARATOR
Intervention: manidipine 20 mg o.d. for 4 weeks
Number of subjects: 55
Study 16060411 — intervention group
Group type: COMPARATOR
Intervention: delapril 30 mg b.i.d. for 4 weeks
Number of subjects: 55
Study 16060411 — intervention group
Group type: EXPERIMENTAL
Intervention: fixed combination of manidipine 10 mg plus delapril 30 mg o.d. for 8 weeks
Number of subjects: 55
Study 12403690 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 10
Study 12403690 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 10
Study 12403690 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Budesonide (combination)
Number of subjects: 10
Study 12403690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10879210 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Case Management (ICM)
Number of subjects: 483
Study 10879210 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment services
Number of subjects: 483
Study 8972324 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque)
Number of subjects: 16
Study 8972324 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque)
Number of subjects: 16
Study 8972324 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 16
Study 1729855 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2312
Study 1729855 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2312
Study 6420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 32
Study 6420825 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 32
Study 31126327 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings (treatment with benznidazole)
Number of subjects: 833
Study 31126327 — intervention group
Group type: COMPARATOR
Intervention: Non-siblings (controls)
Number of subjects: 833
Study 29469212 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing or pay-for-performance (P4P) methods
Number of subjects: 0
Study 29469212 — intervention group
Group type: COMPARATOR
Intervention: Earlier contracting/P4P models
Number of subjects: 0
Study 29469212 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data from key informant interviews
Number of subjects: 0
Study 29469212 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracting and P4P approaches
Number of subjects: 0
Study 26370560 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized minimal acupuncture in LI4
Number of subjects: 144
Study 26370560 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture (Sifeng, LI4, ST36)
Number of subjects: 144
Study 26370560 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 144
Study 24940305 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (3 times/week for 3 months)
Number of subjects: 50
Study 24940305 — intervention group
Group type: COMPARATOR
Intervention: Mild aerobic exercise training (3 times/week for 3 months)
Number of subjects: 50
Study 24940305 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between moderate and mild aerobic exercise training
Number of subjects: 50
Study 21492178 — intervention group
Group type: EXPERIMENTAL
Intervention: P-Capt-filtered RBCs
Number of subjects: 43
Study 19139444 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE reminder‐feedback and educational outreach intervention
Number of subjects: 1468
Study 18693600 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg per day)
Number of subjects: 100
Study 18693600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15151516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX) 180 mg
Number of subjects: 12
Study 15151516 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (ML) 10 mg
Number of subjects: 12
Study 15151516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX) 180 mg + Montelukast (ML) 10 mg
Number of subjects: 12
Study 15151516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 11557915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 13
Study 11557915 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 5 mg
Number of subjects: 13
Study 8228340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer vaccine (100-fold greater than standard titer)
Number of subjects: 1972
Study 8228340 — intervention group
Group type: COMPARATOR
Intervention: Medium-titer vaccine (10-fold greater than standard titer)
Number of subjects: 1972
Study 3803483 — intervention group
Group type: EXPERIMENTAL
Intervention: Judging tense of printed verbs (V)
Number of subjects: 40
Study 3803483 — intervention group
Group type: EXPERIMENTAL
Intervention: Judging symmetry of spatial patterns (S)
Number of subjects: 40
Study 3803483 — intervention group
Group type: EXPERIMENTAL
Intervention: Common ensemble for both tasks (V and S)
Number of subjects: 40
Study 3803483 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation interval prior to verbal and spatial tasks
Number of subjects: 40
Study 28782306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition behaviour change communication (BCC)
Number of subjects: 2341
Study 28782306 — intervention group
Group type: COMPARATOR
Intervention: Non-BCC groups
Number of subjects: 2341
Study 27670866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Eating Intervention (MEI)
Number of subjects: 37
Study 27670866 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study 24060855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass)
Number of subjects: 23
Study 23682661 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 30 mg QD
Number of subjects: 700
Study 23682661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 20181971 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated antiretroviral therapy during tuberculosis therapy (combined integrated-therapy groups)
Number of subjects: 642
Study 20181971 — intervention group
Group type: COMPARATOR
Intervention: Sequential antiretroviral therapy after completion of tuberculosis therapy (sequential-therapy group)
Number of subjects: 642
Study 17997391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g)
Number of subjects: 424
Study 17997391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study 16310911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-tibial amputations group
Number of subjects: 42
Study 16310911 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 14575193 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE-15 in a four-page survey instrument
Number of subjects: 1445
Study 14575193 — intervention group
Group type: COMPARATOR
Intervention: PPE-15 in a 12-page survey instrument
Number of subjects: 1445
Study 11078178 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 to 10 mg twice a day
Number of subjects: 464
Study 11078178 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 to 20 mg twice a day
Number of subjects: 464
Study 11078178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 8712033 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic medication (doses above 2000 mg chlorpromazine equivalents daily)
Number of subjects: 111
Study 8712033 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated controls
Number of subjects: 111
Study 1281062 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous salmon calcitonin (100 U Calcitonin Sandoz) for 21 days plus physical treatment and early mobilization
Number of subjects: 50
Study 1281062 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 50
Study 3709030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg/day for 6 days
Number of subjects: 6
Study 3709030 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 6
Study 3709030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole with methylprednisolone
Number of subjects: 6
Study 28922338 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.7 mg/kg bolus over 1 min followed by infusion at 10 μg/kg/min)
Number of subjects: 14
Study 28922338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline bolus)
Number of subjects: 14
Study 28922338 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.2 μg/kg/min infusion)
Number of subjects: 14
Study 27523491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 mL)
Number of subjects: 216
Study 27523491 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 216
Study 24013647 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 325
Study 24013647 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks (Q4W)
Number of subjects: 325
Study 24013647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 24013647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CZP arms (200 mg Q2W and 400 mg Q4W)
Number of subjects: 325
Study 23050829 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month moderate, home-based physical activity program (150 minutes per week) and a behavioral intervention package.
Number of subjects: 156
Study 21905974 — intervention group
Group type: EXPERIMENTAL
Intervention: MR enterography (MRE)
Number of subjects: 50
Study 21905974 — intervention group
Group type: COMPARATOR
Intervention: CT enterography (CTE)
Number of subjects: 50
Study 19161605 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme (24 sessions; 2 sessions a week, 60 minutes per session)
Number of subjects: 424
Study 19161605 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme
Number of subjects: 424
Study 16733114 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered 30F steel SEMS
Number of subjects: 100
Study 16733114 — intervention group
Group type: COMPARATOR
Intervention: 10F polyethylene (PE) stents
Number of subjects: 100
Study 15116824 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation (Group B)
Number of subjects: 40
Study 10779091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg daily
Number of subjects: 40
Study 10779091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9484000 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemolytic ocular film (HOF)
Number of subjects: 248
Study 9484000 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 248
Study 8222743 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid bandage ('Scotchrap')
Number of subjects: 136
Study 8222743 — intervention group
Group type: COMPARATOR
Intervention: Standard adhesive tape treatment
Number of subjects: 136
Study 3518772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenclofenac at 600 mg day-1
Number of subjects: 18
Study 3518772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenclofenac at 1200 mg day-1
Number of subjects: 18
Study 3518772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenclofenac at 1800 mg day-1
Number of subjects: 18
Study 30286820 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (20 mg/day)
Number of subjects: 102
Study 30286820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 102
Study 30286820 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol + Fenofibrate
Number of subjects: 102
Study 30286820 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 102
Study 30286820 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 102
Study 26626320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (optimal/maximum dose <16 mg/24h)
Number of subjects: 60
Study 26626320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 60
Study 26626320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24185607 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled levobupivacaine 1.25 mg/ml via i.p. catheter as needed (maximum once per hour) with continuous saline infusion 10 ml/h
Number of subjects: 40
Study 24185607 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of levobupivacaine 1.25 mg/ml 10 ml/h and bolus saline as needed
Number of subjects: 40
Study 24185607 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled levobupivacaine
Number of subjects: 40
Study 24185607 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of levobupivacaine
Number of subjects: 40
Study 22371462 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in SUPPORT trial
Number of subjects: 1316
Study 22371462 — intervention group
Group type: COMPARATOR
Intervention: Eligible but not enrolled infants
Number of subjects: 1316
Study 20022262 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 24
Study 20022262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17725600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (proton pump inhibitor) for 4 weeks
Number of subjects: 41
Study 17725600 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 normal subjects)
Number of subjects: 41
Study 15851916 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) plus an optimized background regimen (OBR)
Number of subjects: 0
Study 15851916 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) continued after HIV RNA level returns to pretreatment baseline
Number of subjects: 0
Study 15851916 — intervention group
Group type: COMPARATOR
Intervention: Optimized background regimen (OBR) alone
Number of subjects: 0
Study 12416946 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide added to existing methotrexate therapy
Number of subjects: 0
Study 12416946 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to existing methotrexate therapy
Number of subjects: 0
Study 10628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal administration with financial incentive
Number of subjects: 1594
Study 10628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration with financial incentive
Number of subjects: 1594
Study 10628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic visit administration with financial incentive
Number of subjects: 1594
Study 10628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal administration without financial incentive
Number of subjects: 1594
Study 10628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration without financial incentive
Number of subjects: 1594
Study 10628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic visit administration without financial incentive
Number of subjects: 1594
Study 8845402 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV vaccine
Number of subjects: 142
Study 8845402 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oral acyclovir (ACV)
Number of subjects: 142
Study 1775083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal spray (4 doses of an oil‐based P solution at a concentration of 2 mg/0.1 ml, total dose approximately 11 mg of P)
Number of subjects: 20
Study 1775083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment (quantity 0.1 ml, P concentration 20 mg/0.1 ml)
Number of subjects: 20
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 201
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 201
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 201
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 201
Study 7068938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (all doses)
Number of subjects: 201
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 201
Study 7068938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 201
Study 29948276 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPF + EMD
Number of subjects: 30
Study 29948276 — intervention group
Group type: COMPARATOR
Intervention: SCPF
Number of subjects: 30
Study 27822684 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 663
Study 27822684 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus cisplatin (CS)
Number of subjects: 663
Study 25524950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine administered in the evening (2200 h)
Number of subjects: 10
Study 25524950 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine administered in the morning (1000 h)
Number of subjects: 10
Study 25022120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating manipulation
Number of subjects: 120
Study 25022120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting-thrusting manipulation
Number of subjects: 120
Study 25022120 — intervention group
Group type: COMPARATOR
Intervention: Corrective lenses
Number of subjects: 120
Study 22249915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 400
Study 22249915 — intervention group
Group type: COMPARATOR
Intervention: Standardized (attention control)
Number of subjects: 400
Study 19300303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope‐labelled nicotine infusion
Number of subjects: 139
Study 16776576 — intervention group
Group type: EXPERIMENTAL
Intervention: phVEGF165 (vascular endothelial growth factor gene‐carrying plasmid)
Number of subjects: 54
Study 16776576 — intervention group
Group type: COMPARATOR
Intervention: placebo (0.9% NaCl)
Number of subjects: 54
Study 15478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum sleeve (heat-retaining sleeve)
Number of subjects: 52
Study 15478166 — intervention group
Group type: COMPARATOR
Intervention: Placebo sleeve (standard cotton/elastane sleeve)
Number of subjects: 52
Study 15478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum sleeve (heat-retaining sleeve) with correct belief
Number of subjects: 52
Study 15478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum sleeve (heat-retaining sleeve) with incorrect belief
Number of subjects: 52
Study 11771005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-conducted stimuli at 40- and 50-dB
Number of subjects: 5
Study 11771005 — intervention group
Group type: COMPARATOR
Intervention: Conductive hearing loss
Number of subjects: 5
Study 9341413 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose solution during the first 3 days of life in addition to being breastfed
Number of subjects: 180
Study 9341413 — intervention group
Group type: COMPARATOR
Intervention: Exclusively breastfed nonglucose water group (NGW)
Number of subjects: 180
Study 8428871 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5, 10, 15, and 20 mg
Number of subjects: 31
Study 8428871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8428871 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 31
Study 2889353 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (25 Gy over 5-7 days)
Number of subjects: 694
Study 2889353 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 694
Study 29332677 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep (0000-0800 hours) and normal meal timing (1, 5, 11, and 12.5 hours after awakening)
Number of subjects: 6
Study 29332677 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sleep (0330-1130 hours) and late meal timing (4.5, 8.5, 14.5, and 16 hours after awakening)
Number of subjects: 6
Study 29332677 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep and late meal timing
Number of subjects: 6
Study 29332677 — intervention group
Group type: COMPARATOR
Intervention: Late sleep and normal meal timing
Number of subjects: 6
Study 29332677 — intervention group
Group type: COMPARATOR
Intervention: Late sleep and late meal timing
Number of subjects: 6
Study 29267415 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioural Intervention (8 sessions applying CBT principles)
Number of subjects: 50
Study 29267415 — intervention group
Group type: COMPARATOR
Intervention: Usual services (Control group)
Number of subjects: 50
Study 25790328 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (150 mg per day)
Number of subjects: 45
Study 25790328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45